Recombinant Human Cadherin-6/KCAD Fc Chimera Protein, CF

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human Cadherin-6/KCAD Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by the ability of the immobilized protein to support the adhesion of Caki‑2 human clear cell carcinoma epithelial cells. When 5 x 10⁴ cells/well are added to Recombinant Human Cadherin-6 Fc Chimera coated plates (5 µg/mL with 100 µL/well), >30% of cells will adhere after 30 minutes at 37° C.
  Optimal concentration depends on cell type as well as the application or research objectives.
• Source: Mouse myeloma cell line, NS0-derived human Cadherin-6/KCAD protein
  

  Human Cadherin-6 (Thr22-Ala615 & Ser54-Ala615) Accession # P55285	IEGRMD	Human IgG1 (Pro100-Lys330)	6-His tag
  N-terminus			C-terminus

• Accession #: P55285
• N-terminal Sequence: Thr22 & Ser54
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Gene: CDH6
• Purity: >85%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 93.7 kDa (pro), 90 kDa (mature).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 120-140 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >85%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Reconstitution Instructions: Reconstitute at 100 μg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human Cadherin-6/KCAD Fc Chimera Protein, CF

• cadherin 6, type 2, K-cadherin (fetal kidney)
• cadherin, fetal kidney
• Cadherin6
• Cadherin-6
• CDH6
• KCAD
• K-cadherin (fetal kidney)
• K-Cadherin

Background

Cadherin-6, also known as KCAD or K-Cadherin, is a 110-120 kDa type I transmembrane glycoprotein belonging to the classical Cadherin superfamily of calcium-dependent adhesion molecules. Cadherins are involved in multiple processes including embryonic development, cell migration, and maintenance of epithelial integrity (1, 2). Human Cadherin-6 is synthesized with an 18 amino acid (aa) signal peptide and a 35 aa N-terminal propeptide. The mature cell surface-expressed protein consists of a 562 amino acid (aa) extracellular domain (ECD) that contains five tandem Cadherin repeats, a 21 aa transmembrane segment, and a 154 aa cytoplasmic domain (3). Within the ECD, human Cadherin-6 shares 96% and 98% aa sequence identity with mouse and rat Cadherin-10, respectively. Alternate splicing of the human Cadherin-6 mRNA generates additional isoforms with deletions in the extracellular region or a substituted and truncated cytoplasmic domain (4). It interacts homotypically as well as heterotypically with Cadherin-9 and more weakly with Cadherins-7, -10, and -14 (5, 6). Cadherin-6 is expressed primarily in the kidney and brain, both during development and in the adult (3, 7-9). It is enriched in renal proximal tubule epithelial cells and their precursors at sites of cell-cell contact as well as on basolateral membranes (8, 10, 11). In the nervous system, Cadherin-6 is neuronally expressed in discrete regions of the neural plate, neural crest cells that give rise to peripheral nerves, and the brain (7, 12). Cadherin-6 is additionally expressed in the developing retina, osteoclasts and their progenitors, ovarian epithelium, and endometrium during the follicular phase of the menstrual cycle (4, 13-15). It is also expressed in carcinomas of the kidney, ovary, and liver (3, 10, 11, 14).

1. Pokutta, S. and W.I. Weis (2007) Annu. Rev. Cell Dev. Biol. 23:237.
2. Gumbiner, B.M. (2005) Nat. Rev. Mol. Cell Biol. 6:622.
3. Shimoyama, Y. et al. (1995) Cancer Res. 55:2206.
4. Mbalaviele, G.  et al. (1998) J. Cell Biol.  141:1467.
5. Shimoyama, Y. et al. (2000) Biochem. J. 349:159.
6. Shimoyama, Y. et al. (1999) J. Biol. Chem. 274:11987.
7. Inoue, T. et al. (1998) Dev. Dyn. 211:338.
8. Xiang Y.-Y. et al. (1994) Cancer Res. 54:3034.
9. Cho, E.A. et al. (1998) Development 125:803.
10. Paul, R. et al. (1997) Cancer Res. 57:2741.
11. Shimazui, T. et al. (2000) Eur. Urol. 38:331.
12. Inoue, T. et al. (1997) Dev. Biol. 183:183.
13. Ruan, G. et al. (2006) Mech. Dev. 123:881.
14. Sellar, G.C. et al. (2001) Cancer Res.  61:6977.
15. Getsios, S. et al. (1998) Dev. Dyn. 211:238.

Publications for Cadherin-6/KCAD (2715-CA)(2)

Publications using 2715-CA

• Suzuki, H;Nagase, S;Saito, C;Takatsuka, A;Nagata, M;Honda, K;Kaneda, Y;Nishiya, Y;Honda, T;Ishizaka, T;Nakamura, K;Nakada, T;Abe, Y;Agatsuma, T; Raludotatug Deruxtecan, a CDH6-Targeting Antibody-Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, is Efficacious in Human Ovarian and Kidney Cancer Models Molecular cancer therapeutics 2024-01-11 [PMID: 38205802] (ELISA Capture, N/A)
• Dunne E, Spring CM, Reheman A, Jin W, Berndt MC, Newman DK, Newman PJ, Ni H, Kenny D Cadherin 6 has a functional role in platelet aggregation and thrombus formation. Arterioscler. Thromb. Vasc. Biol., 2012-04-26;32(7):1724-31. 2012-04-26 [PMID: 22539596] (Bioassay, Human, Mouse)

Bioinformatics

• Gene Symbol: CDH6
• Uniprot:
  • P55285()